137 related articles for article (PubMed ID: 22102461)
1. Cost analysis of myasthenia gravis from a large U.S. insurance database.
Guptill JT; Marano A; Krueger A; Sanders DB
Muscle Nerve; 2011 Dec; 44(6):907-11. PubMed ID: 22102461
[TBL] [Abstract][Full Text] [Related]
2. Estimated cost of treating myasthenia gravis in an insured U.S. population.
Guptill JT; Sharma BK; Marano A; Soucy A; Krueger A; Sanders DB
Muscle Nerve; 2012 Mar; 45(3):363-6. PubMed ID: 22334170
[TBL] [Abstract][Full Text] [Related]
3. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.
Pelletier EM; Ogale S; Yu E; Brunetta P; Garg J
Clin Ther; 2009 Nov; 31(11):2653-64. PubMed ID: 20110008
[TBL] [Abstract][Full Text] [Related]
4. Healthcare utilization and costs of patients with rosacea in an insured population.
Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
[TBL] [Abstract][Full Text] [Related]
5. Excess costs associated with patients with pulmonary arterial hypertension in a US privately insured population.
Kirson NY; Birnbaum HG; Ivanova JI; Waldman T; Joish V; Williamson T
Appl Health Econ Health Policy; 2011 Sep; 9(5):293-303. PubMed ID: 21875160
[TBL] [Abstract][Full Text] [Related]
6. Healthcare resource utilization among haemophilia A patients in the United States.
Valentino LA; Pipe SW; Tarantino MD; Ye X; Xiong Y; Luo MP
Haemophilia; 2012 May; 18(3):332-8. PubMed ID: 22044662
[TBL] [Abstract][Full Text] [Related]
7. Patient demographics and health plan paid costs in chronic inflammatory demyelinating polyneuropathy.
Guptill JT; Bromberg MB; Zhu L; Sharma BK; Thompson AR; Krueger A; Sanders DB
Muscle Nerve; 2014 Jul; 50(1):47-51. PubMed ID: 24639235
[TBL] [Abstract][Full Text] [Related]
8. Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis.
Yu AP; Yang H; Wu EQ; Setyawan J; Mocarski M; Blum S
J Med Econ; 2011; 14(3):315-23. PubMed ID: 21500975
[TBL] [Abstract][Full Text] [Related]
9. Inpatient cost analysis for treatment of myasthenia gravis.
Omorodion JO; Pines JM; Kaminski HJ
Muscle Nerve; 2017 Dec; 56(6):1114-1118. PubMed ID: 28239867
[TBL] [Abstract][Full Text] [Related]
10. Healthcare costs among patients with chronic constipation: a retrospective claims analysis in a commercially insured population.
Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT; Doshi JA
J Med Econ; 2014 Feb; 17(2):148-58. PubMed ID: 24168640
[TBL] [Abstract][Full Text] [Related]
11. Patient characteristics and prescription fill patterns for allergic rhinitis medications, with a focus on montelukast, in a commercially insured population.
Bollinger ME; Diette GB; Chang CL; Stephenson JJ; Sajjan SG; Fan T; Allen-Ramey FC
Clin Ther; 2010 Jun; 32(6):1093-102. PubMed ID: 20637964
[TBL] [Abstract][Full Text] [Related]
12. Identification of patients receiving peritoneal dialysis using health insurance claims data.
Berger A; Edelsberg J; Inglese G; Bhattacharyya S; Oster G
Clin Ther; 2009 Jun; 31(6):1321-34. PubMed ID: 19695397
[TBL] [Abstract][Full Text] [Related]
13. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
[TBL] [Abstract][Full Text] [Related]
14. Estimates of the direct cost per case and overall burden of trichomoniasis for the employer-sponsored privately insured women population in the United States, 2001 to 2005.
Owusu-Edusei K; Tejani MN; Gift TL; Kent CK; Tao G
Sex Transm Dis; 2009 Jun; 36(6):395-9. PubMed ID: 19556934
[TBL] [Abstract][Full Text] [Related]
15. Cost of diabetes: comparison of disease-attributable and matched cohort cost estimation methods.
Tunceli O; Wade R; Gu T; Bouchard JR; Aagren M; Luo W
Curr Med Res Opin; 2010 Aug; 26(8):1827-34. PubMed ID: 20491613
[TBL] [Abstract][Full Text] [Related]
16. The direct costs of untreated comorbid insomnia in a managed care population with major depressive disorder.
Asche CV; Joish VN; Camacho F; Drake CL
Curr Med Res Opin; 2010 Aug; 26(8):1843-53. PubMed ID: 20515321
[TBL] [Abstract][Full Text] [Related]
17. Cost of patients with primary open-angle glaucoma: a retrospective study of commercial insurance claims data.
Lee PP; Levin LA; Walt JG; Chiang T; Katz LM; Dolgitser M; Doyle JJ; Stern LS
Ophthalmology; 2007 Jul; 114(7):1241-7. PubMed ID: 17306876
[TBL] [Abstract][Full Text] [Related]
18. Cost and utilization outcomes of opioid-dependence treatments.
Baser O; Chalk M; Fiellin DA; Gastfriend DR
Am J Manag Care; 2011 Jun; 17 Suppl 8():S235-48. PubMed ID: 21761950
[TBL] [Abstract][Full Text] [Related]
19. Health and economic burden of metabolic comorbidity among individuals with bipolar disorder.
Centorrino F; Mark TL; Talamo A; Oh K; Chang J
J Clin Psychopharmacol; 2009 Dec; 29(6):595-600. PubMed ID: 19910727
[TBL] [Abstract][Full Text] [Related]
20. Infliximab drug and infusion costs among patients with Crohn's disease in a commercially-insured setting.
Ollendorf DA; Lidsky L
Am J Ther; 2006; 13(6):502-6. PubMed ID: 17122530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
